A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010)

被引：23
|
作者：
Uzzo, Robert
Bex, Axel
Rini, Brian I.
Albiges, Laurence
Suarez, Cristina
Donaldson, Frank
Asakawa, Takashi
Schiff, Christina
Pal, Sumanta K.
机构：
[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[3] Cleveland Clin, Taussig Canc Insitute, Cleveland, OH 44106 USA
[4] Inst Gustave Roussy, Villejuif, France
[5] Vall dHebron Univ Hosp Inst Oncol VHIO, Barcelona, Spain
[6] F Hoffmann La Roche Ltd, Basel, Switzerland
[7] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA
[8] City Hope Comprehens Canc Ctr, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS4598
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4598
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients.
    Escudier, Bernardi.
    Rini, Brian I.
    Martini, Jean-Francois
    Chang, Wayne Yen-Hwa
    Breza, Jan
    Magheli, Ahmed
    Svedman, Christer
    Lopatin, Margarita
    Knezevic, Dejan
    Goddard, Audrey D.
    English, Patricia A.
    Li, Rachel
    Lin, Xun
    Valota, Olga
    Carteni, Giacomo
    Staehler, Michael D.
    Motzer, Robert J.
    Ravaud, Alain
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)
    Ravaud, A.
    Motzer, R. J.
    Pandha, H. S.
    Staehler, M.
    George, D.
    Pantuck, A. J.
    Patel, A.
    Chang, Y-H.
    Escudier, B.
    Donskov, F.
    Magheli, A.
    Carteni, G.
    Laguerre, B.
    Tomczak, P.
    Breza, J.
    Gerletti, P.
    Lin, X.
    Lechuga, M.
    Martini, J-F.
    Patard, J-J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) plus bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
    Kudo, Masatoshi
    Chen, Minshan
    Chow, Pierce K. H.
    Kaseb, Ahmed Omar
    Lee, Han Chu
    Yopp, Adam C.
    Becker, Lars
    Painter, Sairy Hernandez
    Kovic, Bruno
    Lian, Qinshu
    Ma, Ning
    Wu, Chun
    Qin, Shukui
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Molecular correlates differentiate response to atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun): results from a Phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
    Gruellich, C.
    Rini, B. I.
    Huseni, M.
    Atkins, M.
    McDermott, D.
    Powles, T.
    Escudier, B.
    Banchereau, R.
    Liu, L. -F.
    Leng, N.
    Fan, J.
    Doss, J.
    Nalle, S.
    Carroll, S.
    Li, S.
    Schiff, C.
    Green, M.
    Motzer, R. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 148 - 148
  • [25] Adjuvant sunitinib (SU) in patients (pts) with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial
    Staehler, M.
    Motzer, R. J.
    George, D. J.
    Pandha, H. S.
    Donskov, F.
    Escudier, B.
    Kliment, J.
    Pantuck, A. J.
    Patel, A.
    Deannuntis, L.
    Bhattacharyya, H.
    Lin, X.
    Lechuga, M.
    Serfass, L.
    Patard, J-J.
    Ravaud, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Molecular correlates differentiate response to atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
    Rini, B. I.
    Huseni, M.
    Atkins, M. B.
    McDermott, D. F.
    Powles, T. B.
    Escudier, B.
    Banchereau, R.
    Liu, L-F.
    Leng, N.
    Fan, J.
    Doss, J.
    Nalle, S.
    Carroll, S.
    Li, S.
    Schiff, C.
    Green, M.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2018, 29 : 724 - 725
  • [27] Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results
    Gross-Goupil, M.
    Kwon, T. G.
    Eto, M.
    Ye, D.
    Miyake, H.
    Seo, S. I.
    Byun, S. S.
    Lee, J. L.
    Master, V.
    Jin, J.
    Debenedetto, R.
    Linke, R.
    Casey, M.
    Rosbrook, B.
    Frean, M. J. Lechuga
    Valota, O.
    Grande, E.
    Quinn, D. I.
    ANNALS OF ONCOLOGY, 2018, 29 : 303 - 303
  • [28] SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC): A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF SUNITINIB VS. PLACEBO IN SUBJECTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC)
    Ravaud, A.
    Motzer, R. J.
    Pandha, H.
    Staehler, M.
    George, D. J.
    Pantuck, A.
    Patel, A.
    Gerletti, P.
    Chen, L.
    Patard, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 292 - 293
  • [29] IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
    Hussain, Maha H. A.
    Powles, Thomas
    Albers, Peter
    Castellano, Daniel
    Daneshmand, Siamak
    Gschwend, Juergen
    Nishiyama, Hiroyuki
    Oudard, Stephane
    Tayama, Darren
    Davarpanah, Nicole N.
    Degaonkar, Viraj
    Shi, Yi
    Mariathasan, Sanjeev
    Grivas, Petros
    Peter, H. O.
    Rosenberg, Jonathan E.
    Geynisman, Daniel M.
    Hoffman-Censits, Jean H.
    Peter Petrylak, Daniel
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) plus bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
    Yopp, A.
    Kudo, M.
    Chen, M.
    Cheng, A-L.
    Kaseb, A. O.
    Lee, H. C.
    Qin, S.
    Cha, E.
    Hack, S. P.
    Lian, Q.
    Spahn, J.
    Wu, C.
    Chow, P.
    ANNALS OF ONCOLOGY, 2024, 35 : 1230 - 1230
12345